March 6, 2017 / 12:21 PM / 6 months ago

BRIEF-Concert Pharmaceuticals qtrly loss per share $ 0.54

March 6 (Reuters) - Concert Pharmaceuticals Inc

* Concert pharmaceuticals reports year ended 2016 financial results

* Concert pharmaceuticals inc - ctp-543 on track to advance into phase 2a trial

* Qtrly loss per share $ 0.54

* Concert pharmaceuticals- expects cash, cash equivalents and investments as of december 31, 2016, to be sufficient to fund company through q2 of 2018

* Concert pharmaceuticals inc - upon closing of ctp-656 asset purchase agreement, pro forma cash is expected to be sufficient to fund company into 2021 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below